Apogenix GmbH of Heidelberg, Germany has begun recruitment for a Phase 2 study of a compound for treating glioblastoma multiforme, the most aggressive type of primary brain tumour. Interim results are expected in the first half of 2011. ---Subscribe to MedNous to access this article--- Company News
